Navigation Links
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
Date:4/10/2008

at CV Therapeutics has received approval for in just over two years," stated Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "We are very excited to have Astellas -- the clear market leader in pharmacologic stress for MPI -- commercializing Lexiscan."

"We are extremely pleased that the FDA has approved Lexiscan, an exciting new option for diagnosing coronary artery disease in patients who cannot undergo an exercise stress test," said Yoshihiko Hatanaka, president and chief executive officer of Astellas Pharma US, Inc. "We are preparing to launch Lexiscan soon after this approval in order to provide clinicians with this important new option for patients who need pharmacologic stress agents for MPI studies."

Lexiscan Clinical Trials

In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted with Lexiscan were similar to MPI studies conducted with Adenoscan(R) (adenosine injection).

Lexiscan was generally well-tolerated in both Phase III studies. The most common adverse events reported in patients who received Lexiscan were shortness of breath, headache, flushing, chest discomfort, dizziness and nausea.

About Lexiscan

Lexiscan is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI studies in patients unable to undergo adequate exercise stress. Lexiscan was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan should not be administered to patients with second- or third-degree AV block or sinus node dysfunction who do not have a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan, induce arterial vasodilati
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
5. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
9. Mercury Therapeutics Patents Filed
10. Cell Therapeutics, Inc. Announces Filing of Form 10-K
11. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 ... market for antithrombotic drugs will reach $22.4bn in 2019. ... Drugs: World Industry and Market Prospects 2015-2025 ... of that investigation is to provide forecasts and qualitative ... business information publisher and consultancy in London, ...
(Date:5/1/2015)... ALBANY, N.Y. , May 1, 2015 ... today that William S. Marth , AMRI,s President ... of America Merrill Lynch 2015 Health Care Conference on ... A live audio webcast of the presentation can ... http://ir.amriglobal.com/events.cfm?CalendarID=2          The webcast will be ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 /PRNewswire/ ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on Wednesday, ... be accessed via a live webcast on the United Therapeutics ...
(Date:4/30/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... solutions for the detection of foodborne pathogens, announced plans ... of 2015 on May 7, 2015 after the close ... also host a conference call at 4:30 p.m. Eastern ... quarter financial results. During the conference call, material information ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... - GeneNews Limited (TSX: GEN), a company ... the early detection of diseases and personalized ... Laboratories, leading providers of laboratory services, information ... specimen collection services for ColonSentry(TM), the world,s ...
... November 20 ,Debiopharm Group (Debiopharm), a ... serious medical conditions and particularly,oncology, and ... fully integrated, global biotech focused on ... development from target identification and,validation to ...
... Discovery S.A., a Swiss biotech firm and Laborium Biopharma, a subsidiary ... development and optimization of protein bioprocess production and scale-up. , ... ... S.A., a Swiss biotech firm and Laborium Biopharma, a subsidiary of ...
Cached Biology Technology:GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs 2GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs 3GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs 4Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement 2
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Patients with symptomatic moderate asthma who were treated ... antibody, experienced significantly fewer disease exacerbations than individuals ... the first issue for October 2006 of the ... published by the American Thoracic Society. , Trevor ...
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... theories regarding consciousness, emotion and quality of life ... (ALS, also known as 'Lou Gerhig's disease') are ... interaction. ALS is a progressive disease that destroys ... latest issue of Psychophysiology. The article reviews the ...
Cached Biology News:Monoclonal antibody reduces exacerbations in asthmatics 2T-ray breakthrough could make detecting disease far easier 2Computer with brain connections changing quality of life of paralyzed 2
... fixative useful for routine procedures. Hollandes contains ... and will decalcify small bone specimens. Tissue ... stained successfully with most stains, and the ... blood cell membranes and cosinophil and endocrine ...
... gold standard for automated bioresearch: Developed ... applications • Based on decades of ... accessories designed for bioresearch • Holographic ... Versatility, reliability and ease-of-use • Pulsed ...
... BODIPY FL ATP-Gamma-S binds to ATP-binding ... the BODIPY FL fluorophore was linked ... addition to its potential use for ... thioether is an important new substrate ...
... the patent-pending Formula Predictor software takes ... isotope pattern verification, and unique fragment-ion ... correct formula for unknown components. ... formulae from mass spec data often ...
Biology Products: